Unknown

Dataset Information

0

Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.


ABSTRACT: To assess the short-term tolerability of lorcaserin alone or with two dose regimens of phentermine.This was a 12-week, randomized, double-blind, pilot safety study of N?=?238 nondiabetic patients with obesity or overweight with ?1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice daily (LOR BID+PHEN BID). Patients reporting???1 of 9 potentially serotonergic adverse events (AEs), mean weight loss (WL), and ?5% WL are reported.N?=?238 were randomized, and N?=?235 were treated. N?=?94 reported potentially serotonergic AEs: 37.2% LOR BID, 42.3% LOR BID+PHEN QD, and 40.5% LOR BID+PHEN BID. AEs leading to discontinuation were reported approximately twice as often in the LOR BID+PHEN BID group versus the LOR BID group. Mean WL was 3.5?kg/3.3%, 7.0?kg/6.7%, and 7.6?kg/7.2% for LOR BID, LOR BID+PHEN QD, and LOR BID+PHEN BID, respectively. At least 5% WL was achieved by 28.2% LOR BID, 59.0% LOR BID+PHEN QD (P?=?0.0002 vs. LOR BID), and 70.9% LOR BID+PHEN BID (P?

SUBMITTER: Smith SR 

PROVIDER: S-EPMC5518190 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.

Smith Steven R SR   Garvey W Timothy WT   Greenway Frank L FL   Zhou Sharon S   Fain Randi R   Pilson Robert R   Fujioka Ken K   Aronne Louis J LJ  

Obesity (Silver Spring, Md.) 20170501 5


<h4>Objective</h4>To assess the short-term tolerability of lorcaserin alone or with two dose regimens of phentermine.<h4>Methods</h4>This was a 12-week, randomized, double-blind, pilot safety study of N = 238 nondiabetic patients with obesity or overweight with ≥1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice daily (LOR BID+PHEN BID). Patients reporting ≥ 1 of 9 potentially serotonergic advers  ...[more]

Similar Datasets

| S-EPMC5788290 | biostudies-literature
| S-EPMC5891125 | biostudies-other
| S-EPMC6677860 | biostudies-literature
| S-EPMC5043601 | biostudies-literature
| S-EPMC8399671 | biostudies-literature
| S-EPMC3504311 | biostudies-other
| S-EPMC6658913 | biostudies-literature
| S-EPMC5778780 | biostudies-literature
| S-EPMC6716483 | biostudies-literature
| S-EPMC4431914 | biostudies-literature